EcoDrugPlus

Cyclin-Dependent Kinase 2

Ensembl ID : ENSDARG00000026577
Gene Symbol: CDK2
56 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Cyclin-Dependent Kinase 4

Ensembl ID : ENSDARG00000087937
Gene Symbol: CDK4
24 Enzyme and pathways 5 Cross references
239 Possible Orthologues:

Cyclin-Dependent Kinase 5

Ensembl ID : ENSDARG00000056683
Gene Symbol: CDK5
16 Enzyme and pathways 5 Cross references
169 Possible Orthologues:

Cyclin-Dependent Kinase 6

Ensembl ID : ENSDARG00000070228
Gene Symbol: CDK6
10 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Cyclin-Dependent Kinase 7

Ensembl ID : ENSDARG00000051916
Gene Symbol: CDK7
44 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Cyclin-Dependent Kinase 9 (Cdc2-Related Kinase)

Ensembl ID : ENSDARG00000044811
Gene Symbol: CDK9
17 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSDARG00000058246
Gene Symbol: CYSLTR1
8 Enzyme and pathways 5 Cross references
180 Possible Orthologues:

Cytidine Deaminase A

Ensembl ID : ENSDARG00000111188
Gene Symbol: CDAA
5 Cross references
163 Possible Orthologues:

Cytidine Deaminase B

Ensembl ID : ENSDARG00000038199
Gene Symbol: CDAB
7 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Cytochrome P450, Family 17, Subfamily A, Polypeptide 1

Ensembl ID : ENSDARG00000033566
Gene Symbol: CYP17A1
6 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSDARG00000041348
Gene Symbol: CYP19A1A
9 Enzyme and pathways 5 Cross references
255 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSDARG00000033999
Gene Symbol: CYP26A1
9 Enzyme and pathways 5 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).